semaglutide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42552573
Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.
Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.
- 저자
- Luigi E Adinolfi, Aldo Marrone, Antonio Izzi, Antonio Craxi
- 저널
- Expert review of endocrinology & metabolism
- 공개일
- 2026 Aug 04
- 연구 유형
- 기타
- DOI
- 10.1080/17446651.2026.2714267
문헌 요약
Resmetirom and semaglutide are the first drugs to be approved for the pharmacological treatment of metabolic-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis. However, approval was based on histological endpoints obtained during a relatively short trial period, leaving some important questions unanswered. Resmetirom acts directly on…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.